Silicon Canals
TRENDING
  • Mobility
  • AI
  • FinTech
  • Software & SaaS
No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
No Result
View All Result
Silicon Canals
No Result
View All Result

Two of the world’s largest European pharmaceutical companies team up to hunt for a coronavirus vaccine

Shubham Sharma by Shubham Sharma
April 21, 2020
in News, COVID-19, Health & Medtech, Startups
0
Two of the world’s largest European pharmaceutical companies team up to hunt for a coronavirus vaccine
48
SHARES
LinkedInTwitterWhatsAppFacebook

A couple of weeks ago, WHO released a notification which mentioned 67 vaccine trials are in preclinical evaluation while 3 are being clinically evaluated for the novel coronavirus. This information clearly suggests that the world is zooming ahead to find a vaccine for the pandemic, which is adversely affecting our daily lives. 

Do follow our special coverage on coronavirus over here.

 - Partner content -
Cost of software - The Software house
The cost of building software
Marek Gajda, CTO of The Software House, shares his insights on building high-quality...Show More
Marek Gajda, CTO of The Software House, shares his insights on building high-quality software. Show Less
Read more

The vaccine discovery effort has now received a huge boost as two of the world’s largest Europe-based pharma companies have announced a partnership to hunt for a COVID-19 vaccine. Sanofi and GlaxoSmithKline have announced that they are working together to develop a coronavirus vaccine and potential vaccine trials on humans are scheduled later this year.

Sanofi and GlaxoSmithKline announce partnership to develop coronavirus vaccine

The partnership of the two Europe-based pharma giants doesn’t come as a surprise. They both bring decades of vaccine development experience to the table and together, their market valuation easily crosses $200 billion (€185 billion). Alongside the announcement of their partnership, Sanofi and GlaxoSmithKline (GSK) also said that they aim to commence human trials of a potential coronavirus vaccine later this year, which could be ready for the masses by the second half of 2021. The companies didn’t disclose any financial details of their partnership. 

“As the world’s leading vaccine manufacturer, our No. 1 focus is to help to develop a vaccine,” GlaxoSmithKline CEO Emma Walmsley told the media. “This is, of course, core to the exit plan that the world needs.” Walmsley further added, “Both companies bring significant manufacturing capacity. While we have a lot of work to do, given that this is in an early stage of development, we believe that if we’re successful, we’ll be able to make hundreds of millions of doses annually by the end of next year.”

Sanofi will use an antigen, GSK to provide adjuvant

Sanofi and GSK also revealed how their partnership could lead to the development of a vaccine. Sanofi will use an antigen targeting the coronavirus’ signature spike protein, which are the crowns of bulbous projections that give the coronavirus its signature shape. GSK will provide an adjuvant, which is a pharmacological or immunological agent that can be added to a vaccine for boosting one’s immune response to it and producing more antibodies. This adjuvant can reduce the amount of vaccine needed per dose. 

As per a report by the Business Insider, The US Biomedical Advanced Research and Development Authority (BARDA) has partially funded Sanofi’s vaccine research. BARDA Director Rick Bright said in a statement that this collaboration “holds the potential to lower the vaccine dose to provide vaccine to a greater number of people to end this pandemic, and help the world become better prepared or even prevent future coronavirus outbreaks.”

GSK executives said that even with the pooled resources of the two giant pharma companies, there would most likely be need for multiple vaccines to meet the unprecedented global demand for a coronavirus vaccine.

Image Credits: angellodeco/Shutterstock

Stay tuned to Silicon Canals for more European technology news

close

Want to stay on top of the latest rounds, coolest tech and hottest startups?

Subscribe to our free, daily news blast and stay up-to-date!

Check your inbox or spam folder to confirm your subscription.

 - Partner content -
Nebula CTO Andre Witte
Cloud spend management 😱
Tracking cloud spend can be tricky. Learn from Nebula's CTO Andre Witte how to keep the...Show More
Tracking cloud spend can be tricky. Learn from Nebula's CTO Andre Witte how to keep the costs at bay in 2021. Show Less
Read more
Tags: Health-& Medtechnews
Share2Tweet6SendShare33

Featured events

07apr10:0012:30FeaturedWorkshop: pr for startupsHow to grow your startup with the help of public relations

Partner content | Work with us

Blue Tulip Awards announce 5 finalists in the Food & Water and Education & Employment theme

Impact media foundation 5 Media offers grants up to €100,000 per year to drive a sustainable future

Here’s how cryptocurrency will take over the world

Blue Tulip Awards is driven by purpose: why innovation and equality go hand in hand

Future of coding: CTOs discuss low-code versus custom code software development for their business

Breaking news from Amsterdam | Partner

Amsterdam-based fintech unicorn Mollie enters UK market to helps merchants there grow into Europe post-Brexit

Amsterdam-based HR tech Recruitee takes a “shortcut” to a future unicorn status

Amsterdam-based mobility startup BAQME launches its shared e-box bikes in Rotterdam

Amsterdam’s TomTom resumes share buyback program for remaining €33M; revenue for FY ’20 dips by 25%

  • About Silicon Canals
  • Partner with Silicon Canals
  • Contact us
  • Newsletter
  • Disclaimer
  • Privacy policy
  • Terms & Conditions Silicon Canals

Silicon Canals 2014-2020 | Website: Bright Idiots

No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdam
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact

Silicon Canals 2014-2020 | Website: Bright Idiots

X

This website uses cookies to ensure the best possible experience. We may share this information with our advertising and analytics partners. By clicking 'Accept', you agree to our use of cookies and similar technologies. More info